Anticancer activity of Ashwagandha against human head and neck cancer cell lines

Background The aim of this study was to determine the apoptotic activity of methanol extract of Ashwagandha (MEAG) and in human head and neck squamous cell carcinoma (HNSCC) cells and to investigate the underlying mechanisms. Methods We investigated the effects of MEAG on programmed cell death in HNSCC cells using a Live/Dead assay, detection of nuclear morphologic changes, Mitotracker, siRNA knockdown, and RT‐PCR. Results Treatment with MEAG showed dose‐dependent growth‐inhibitory activity that attribute to caspase‐dependent apoptosis. Loss of mitochondrial membrane potential, release of cytochrome c, and activation of caspase 9 suggested that MEAG leads to activation of mitochondria‐mediated apoptosis. MEAG selectively upregulated the expression of Bim protein at the transcriptional level and induced the translocation of Bim into the mitochondria. Knockdown of Bim by siRNA partially blocked MEAG‐mediated apoptosis. MEAG also caused an increase in truncated Bid (t‐Bid), cleaved caspase‐8, and death receptor 5 (DR5). Interestingly, withaferin A (WA), a bioactive component of MEAG, clearly induced apoptosis accompanied by upregulation of Bim, t‐Bid, caspase‐8, and DR5 similar to the effects of MEAG. Conclusions These suggest that MEAG and WA may be potential natural materials for the treatment of HNSCC.